These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16048929)

  • 1. Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa.
    Brazas MD; Hancock RE
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3222-7. PubMed ID: 16048929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fis Contributes to Resistance of Pseudomonas aeruginosa to Ciprofloxacin by Regulating Pyocin Synthesis.
    Long Y; Fu W; Wang S; Deng X; Jin Y; Bai F; Cheng Z; Wu W
    J Bacteriol; 2020 May; 202(11):. PubMed ID: 32205461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
    Brazas MD; Breidenstein EB; Overhage J; Hancock RE
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4276-83. PubMed ID: 17893152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa.
    Blázquez J; Gómez-Gómez JM; Oliver A; Juan C; Kapur V; Martín S
    Mol Microbiol; 2006 Oct; 62(1):84-99. PubMed ID: 16956383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
    Wolter DJ; Schmidtke AJ; Hanson ND; Lister PD
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2997-3000. PubMed ID: 17517839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological cost of pyocin production during the SOS response in Pseudomonas aeruginosa.
    Penterman J; Singh PK; Walker GC
    J Bacteriol; 2014 Sep; 196(18):3351-9. PubMed ID: 25022851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PrtR homeostasis contributes to Pseudomonas aeruginosa pathogenesis and resistance against ciprofloxacin.
    Sun Z; Shi J; Liu C; Jin Y; Li K; Chen R; Jin S; Wu W
    Infect Immun; 2014 Apr; 82(4):1638-47. PubMed ID: 24491574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin.
    Cirz RT; O'Neill BM; Hammond JA; Head SR; Romesberg FE
    J Bacteriol; 2006 Oct; 188(20):7101-10. PubMed ID: 17015649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between the sensitivity of Pseudomonas aeruginosa and the post-antibiotic effect of sparfloxacin and ciprofloxacin].
    Pastor A; Cantón E; Pemán J
    Rev Esp Quimioter; 1998 Dec; 11(4):333-8. PubMed ID: 9990147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomonas aeruginosa Oligoribonuclease Contributes to Tolerance to Ciprofloxacin by Regulating Pyocin Biosynthesis.
    Chen F; Chen G; Liu Y; Jin Y; Cheng Z; Liu Y; Yang L; Jin S; Wu W
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment.
    Firsov AA; Strukova EN; Portnoy YA; Shlykova DS; Zinner SH
    Int J Antimicrob Agents; 2015 Sep; 46(3):313-8. PubMed ID: 26297633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biofilm culture of Pseudomonas aeruginosa expressing lux genes as a model to study susceptibility to antimicrobials.
    Parveen A; Smith G; Salisbury V; Nelson SM
    FEMS Microbiol Lett; 2001 May; 199(1):115-8. PubMed ID: 11356577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOS-Independent Pyocin Production in P. aeruginosa Is Induced by XerC Recombinase Deficiency.
    Baggett NS; Bronson AS; Cabeen MT
    mBio; 2021 Dec; 12(6):e0289321. PubMed ID: 34809462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity testing of Pseudomonas aeruginosa to ciprofloxacin: comparison of the modified Stokes' method with MIC results obtained by the Etest.
    Galloway A; Wright J; Murphy O; Dickinson G
    J Antimicrob Chemother; 1999 Feb; 43(2):314-5. PubMed ID: 11252344
    [No Abstract]   [Full Text] [Related]  

  • 19. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
    Lee JK; Lee YS; Park YK; Kim BS
    Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.